Nuclear Medicine Global Market Outlook - Trends, Forecast, and Opportunity Assessment (2014-2022)

Nuclear Medicine Global Market Outlook - Trends, Forecast, and Opportunity Assessment (2014-2022)

  • Published: October 2015
  • ID: SMRC15223

The Global Nuclear Medicine Market accounted for $8.8 billion in 2014 and is expected to grow at a CAGR of 9.6% to reach $20.4 billion by 2022. Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. According to World nuclear association, Over 10,000 hospitals across the world use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most commonly used radioisotope in diagnosis is technetium-99, accounting for more than 80% of all nuclear medicine procedures worldwide. Computed X-ray tomography (CT) scans and nuclear medicine contribute 36% of the total radiation exposure and 75% of the medical exposure to the U.S. population, according to a US National Council on Radiation Protection & Measurements report.

Factors driving the nuclear medicine market include advancements in radiotracers, increasing number of patients with cancer and cardiovascular ailment, increasing use of SPECT and PET scan results and alpha radio immunotherapy-based targeted cancer treatment. However, factors such as stringent regulatory guidelines, high capital investment, shorter half-life of radiopharmaceuticals and competition from conventional diagnostic procedures are inhibiting the growth of nuclear medicine market. Technological advancements in neurological applications and increasing demand from emerging countries are likely to create huge opportunities for the market growth.

The Global nuclear medicine market is segmented on the basis of application and geography. Based on the application, the nuclear medicine market is categorized into diagnostics and therapeutics applications. The diagnostic application is further segmented into SPECT and PET market, where SPECT market comprises of cardiology, neurology, thyroid and other diagnostic applications. The PET market comprises of oncology and other PET applications. The therapeutics application is further segmented into thyroid, bone metastasis, endocrine tumors and other therapeutic applications. By geography, it is segmented into North America, Europe, Asia Pacific and Rest of the World. North America followed by the Europe dominates the global nuclear medicine market.

Some of the key players in nuclear medicine market include GE Healthcare (U.K.), Nordion, Inc. (Canada), Bayer Healthcare (Germany), Cardinal Health, Inc. (U.S.), Siemens Healthcare (PETNET) (Germany)., IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Eczacibasi-Monrol Nuclear Products (Turkey), Ashby Gorman Baker Ltd, and Mediso Ltd.

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary        
           
2 Preface         
 2.1 Abstract        
 2.2 Research Scope        
 2.3 Research Methodology       
 2.4 Research Sources       
           
3 Market Trend Analysis        
 3.1 Introduction        
 3.2 Drivers        
 3.3 Restraints        
 3.4 Opportunities        
 3.5 Threats        
           
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers       
 4.3 Threat of substitutes       
 4.4 Threat of new entrants       
 4.5 Competitive rivalry       
           
           
5  Global Nuclear Medicine  Market, By Applications     
 5.1 Introduction        
 5.2 Diagnostics         
  5.2.1 Single proton emission tomography (SPECT)     
   5.2.1.1 Cardiology      
   5.2.1.2 Neurology      
   5.2.1.3 Thyroid       
   5.2.1.4 Other SPECT applications     
  5.2.2 Positron emission tomography (PET)     
   5.2.2.1 Oncology       
   5.2.2.2 Other PET applications     
 5.3 Therapeutics         
  5.3.1 Thyroid        
  5.3.2 Bone metastasis       
  5.3.3 Endocrine tumors        
  5.3.4 Other therapeutic applications     
           
6 Global Nuclear Medicine  Market, By Geography     
 6.1 North America        
  6.1.1 US        
  6.1.2 Canada        
 6.2 Europe        
  6.2.1 Germany        
  6.2.2 France        
  6.2.3 Italy        
  6.2.4 UK        
  6.2.5 Spain        
 6.3 Asia Pacific        
  6.3.1 Japan        
  6.3.2 China        
  6.3.3 India        
  6.3.4 Australia        
  6.3.5 New Zealand       
  6.3.6 Rest of Asia       
 6.4 Rest of the World       
  6.4.1 Latin America       
  6.4.2 Middle East        
  6.4.3 Africa        
  6.4.4 Others        
           
7 Key Developments        
 7.1 Agreements, Partnerships, Collaborations and Joint Ventures   
 7.2 Acquisitions & Mergers       
 7.3 New Product Launch       
 7.4 Expansions        
 7.5 Other Key Strategies       
           
8 Company Profiling        
 8.1 GE Healthcare (U.K.)       
 8.2 Nordion, Inc. (Canada)       
 8.3 Bayer Healthcare (Germany)      
 8.4 Cardinal Health, Inc. (U.S.)       
 8.5 Siemens Healthcare (PETNET) (Germany)     
 8.6 IBA Group (Belgium)       
 8.7 Lantheus Medical Imaging, Inc. (U.S.)      
 8.8 Eczacibasi-Monrol Nuclear Products (Turkey)     
 8.9 Ashby Gorman Baker Ltd       
 8.10 Mediso Ltd.         
           
List of Tables          
1 Global Nuclear Medicine Market Outlook, By Applications (2012-2022) ($MN)  
2 Global Nuclear Medicine Market Outlook, By Diagnostics  (2012-2022) ($MN)   
3 Global Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT)  (2012-2022) ($MN)
4 Global Nuclear Medicine Market Outlook, By Cardiology (2012-2022) ($MN)   
5 Global Nuclear Medicine Market Outlook, By Neurology (2012-2022) ($MN)   
6 Global Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)   
7 Global Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) ($MN) 
8 Global Nuclear Medicine Market Outlook, By Positron emission tomography (PET)  (2012-2022) ($MN)
9 Global Nuclear Medicine Market Outlook, By Oncology (2012-2022) ($MN)   
10 Global Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) ($MN) 
11 Global Nuclear Medicine Market Outlook, By Therapeutics  (2012-2022) ($MN)  
12 Global Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)   
13 Global Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) ($MN)  
14 Global Nuclear Medicine Market Outlook, By Endocrine tumors  (2012-2022) ($MN)  
15 Global Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) ($MN) 
16 North America Nuclear Medicine Market Outlook, By Applications (2012-2022) ($MN)  
17 North America Nuclear Medicine Market Outlook, By Diagnostics  (2012-2022) ($MN)  
18 North America Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT)  (2012-2022) ($MN)
19 North America Nuclear Medicine Market Outlook, By Cardiology (2012-2022) ($MN)  
20 North America Nuclear Medicine Market Outlook, By Neurology (2012-2022) ($MN)  
21 North America Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
22 North America Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) ($MN)
23 North America Nuclear Medicine Market Outlook, By Positron emission tomography (PET)  (2012-2022) ($MN)
24 North America Nuclear Medicine Market Outlook, By Oncology (2012-2022) ($MN)  
25 North America Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) ($MN) 
26 North America Nuclear Medicine Market Outlook, By Therapeutics  (2012-2022) ($MN)  
27 North America Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
28 North America Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) ($MN) 
29 North America Nuclear Medicine Market Outlook, By Endocrine tumors  (2012-2022) ($MN) 
30 North America Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) ($MN)
31 Europe Nuclear Medicine Market Outlook, By Applications (2012-2022) ($MN)  
32 Europe Nuclear Medicine Market Outlook, By Diagnostics  (2012-2022) ($MN)  
33 Europe Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT)  (2012-2022) ($MN)
34 Europe Nuclear Medicine Market Outlook, By Cardiology (2012-2022) ($MN)   
35 Europe Nuclear Medicine Market Outlook, By Neurology (2012-2022) ($MN)   
36 Europe Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)   
37 Europe Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) ($MN) 
38 Europe Nuclear Medicine Market Outlook, By Positron emission tomography (PET)  (2012-2022) ($MN)
39 Europe Nuclear Medicine Market Outlook, By Oncology (2012-2022) ($MN)   
40 Europe Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) ($MN) 
41 Europe Nuclear Medicine Market Outlook, By Therapeutics  (2012-2022) ($MN)  
42 Europe Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)   
43 Europe Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) ($MN)  
44 Europe Nuclear Medicine Market Outlook, By Endocrine tumors  (2012-2022) ($MN)  
45 Europe Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) ($MN) 
46 Asia Pacific Nuclear Medicine Market Outlook, By Applications (2012-2022) ($MN)  
47 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics  (2012-2022) ($MN)  
48 Asia Pacific Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT)  (2012-2022) ($MN)
49 Asia Pacific Nuclear Medicine Market Outlook, By Cardiology (2012-2022) ($MN)  
50 Asia Pacific Nuclear Medicine Market Outlook, By Neurology (2012-2022) ($MN)  
51 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
52 Asia Pacific Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) ($MN) 
53 Asia Pacific Nuclear Medicine Market Outlook, By Positron emission tomography (PET)  (2012-2022) ($MN)
54 Asia Pacific Nuclear Medicine Market Outlook, By Oncology (2012-2022) ($MN)  
55 Asia Pacific Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) ($MN) 
56 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutics  (2012-2022) ($MN)  
57 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
58 Asia Pacific Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) ($MN)  
59 Asia Pacific Nuclear Medicine Market Outlook, By Endocrine tumors  (2012-2022) ($MN) 
60 Asia Pacific Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) ($MN)
61 Rest Of The World Nuclear Medicine Market Outlook, By Applications (2012-2022) ($MN) 
62 Rest Of The World Nuclear Medicine Market Outlook, By Diagnostics  (2012-2022) ($MN) 
63 Rest Of The World Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT)  (2012-2022) ($MN)
64 Rest Of The World Nuclear Medicine Market Outlook, By Cardiology (2012-2022) ($MN)  
65 Rest Of The World Nuclear Medicine Market Outlook, By Neurology (2012-2022) ($MN)  
66 Rest Of The World Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
67 Rest Of The World Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) ($MN)
68 Rest Of The World Nuclear Medicine Market Outlook, By Positron emission tomography (PET)  (2012-2022) ($MN)
69 Rest Of The World Nuclear Medicine Market Outlook, By Oncology (2012-2022) ($MN)  
70 Rest Of The World Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) ($MN)
71 Rest Of The World Nuclear Medicine Market Outlook, By Therapeutics  (2012-2022) ($MN) 
72 Rest Of The World Nuclear Medicine Market Outlook, By Thyroid (2012-2022) ($MN)  
73 Rest Of The World Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) ($MN) 
74 Rest Of The World Nuclear Medicine Market Outlook, By Endocrine tumors  (2012-2022) ($MN) 
75 Rest Of The World Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) ($MN) 

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials